Traws Pharma (NASDAQ: ONTX)
Traws Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Traws Pharma Company Info
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
News & Analysis
Why Onconova Therapeutics Stock Soared Today
Investors are eager to hear more about the biotech's experimental cancer treatments.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
A $25 billion buyout, a long-awaited FDA approval, two positive clinical studies, and one biopharma losing 37% of its value, are this week's top biotech stories.
3 Horrendous Health-Care Stocks This Week
Which health-care stocks experienced the agony of defeat this week?
Why Onconova Therapeutics Inc. Shares Imploded
Onconova Therapeutics reported disappointing phase 3 results for high-risk myelodysplastic syndrome drug rigosertib. Is this sell-off a buying opportunity or a reason to leave and not turn back?
Why Jabil Circuit, Inc., Onconova Therapeutics Inc., and Gogo Inc. Plunged Today
The long-awaited move from the Federal Reserve to cut back on its quantitative easing sent the markets roaring higher, but among the few decliners today, Jabil Circuit dropped almost 21%, Onconova Therapeutics fell 19%, and Gogo declined 16%. Find out why these stocks didn't join in the Fed-induced celebration Wednesday.
Why Onconova Therapeutics Inc. Shares Crashed
Onconova discontinues a late-stage trial for its lead experimental drug. Is this a classic overreaction by emotional traders or a reason to avoid Onconova?
Keep an Eye on Onconova, Enzymotec, DepoMed, and Omeros Today
Onconova, Enzymotec, DepoMed, and Omeros could make health care headlines this morning. Here’s why.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.